ORALLY-ACTIVE NIPECOTAMIDE GLYCOLAMIDE ESTERS FOR THE TREATMENT OF THROMBOSIS DISORDERS

Abstract: Orally-active nipecotamide glycolamide ester derivatives of formula (I) are disclosed as useful in treating platelet-mediated thrombotic disorders.

Description: ORALLY-ACTIVE NIPECOTA IDE GLYCOLAMIDE ESTERS FOR THE TREATMENT OF THROMBOSIS DISORDERS CROSS-REFERENCE TO RELATED APPLICATION This application claims priority from U.S. Serial No. 60/063366, filed October 29, 1997, the contents of which are hereby incorporated by reference. BACKGROUND OF THE INVENTION Platelet aggregation constitutes the initial hemostatic response to curtail bleeding induced by vascular injury. However, pathological extension of this normal hemostatic process can lead to thrombus formation. The final, common pathway in platelet aggregation is the binding of fibrinogen to activated, exposed platelet glycoprotein llb/llla (GPIIb/llla). Agents which interrupt binding of fibrinogen to GPIIb/llla, therefore, inhibit platelet aggregation. These agents are, therefore, useful in treating platelet-mediated thrombotic disorders such as arterial and venous thrombosis, acute myocardial infarction, unstable angina, reocclusion following thrombolytic therapy and angioplasty, inflammation, and a variety of vaso-occlusive disorders. The fibrinogen receptor (GPIIb llla) is activated by stimuli such as ADP, collagen, and thrombin exposing binding domains to two different peptide regions of fibrinogen: alpha-chain Arg-Gly-Asp (RGD) and gamma- chain His-His-Leu-Gly-Gly-Ala-Lys-Gln-Ala-Gly-Asp-Val (HHLGGAKQAGDV, γ400-411 ). Since these peptide fragments themselves have been shown to inhibit fibrinogen binding to GPIIb/llla, a mimetic of these fragments would also serve as an antagonist. In fact, prior to this invention, potent RGD-based antagonists have been revealed which inhibit both fibrinogen binding to GPIIb/llla and platelet aggregation e.g., Ro-438857 (L. Alig, J. Med. Chem. 1992, 35, 4393) has an IC50 of 0.094 μM against in vitro thrombin-induced platelet aggregation. Some of these agents have also shown in vivo efficacy as antithrombotic agents and, in some cases, have been used in conjunction with fibrinolytic therapy e.g., t-PA or streptokinase, as well (J. A. Zablocki, Current Pharmaceutical Design 1995, 1, 533). The glycolamide ester compounds of the present invention are orally- active GPIIb/llla antagonists which exhibit improved oral absorption and in vivo activity over their carboxylic acid congeners. As demonstrated by the results of the pharmacological studies described hereinafter, the compounds show the ability to block fibrinogen binding to isolated GPIIb/lla (ICso's of ca. 0.0005-0.01 μM), inhibit platelet aggregation in vitro in the presence of a variety of platelet stimuli (ICso's of ca. 0.1-1.0 μM vs. thrombin), and furthermore, inhibit ex vivo platelet aggregation in animal models. Additionally, these agents exhibit efficacy in animal thrombosis models as their progenitors had shown ("Nipecotic Acid Derivatives As Antithrombotic Compounds," application Serial No. 08-213772, filed March 16, 1994 and "Carboxamide Derivatives of Pyrrolidine, Piperidine, and Hexahydroazepine for the Treatment of Thrombosis Disorders," application Serial No. 60-016675, filed May 1, 1996). The compounds of the present invention are carboxylic acid glycolamide esters which show efficacy as antithrombotic agents by virtue of their ability to prevent platelet aggregation. Additionally, because the compounds of this invention inhibit integrin-mediated cell-cell or cell-matrix adhesion, they may be useful against inflammation, bone resorption, tumor cell metastasis, etc. (D. Cox, Drug News & Perspectives 1995, 8, 197). DISCLOSURE OF THE INVENTION The present invention is directed to compounds represented by the following general formula (I): (I) wherein A, X, M, R5, R10, and n are as hereinafter defined. The glycolamide ester compounds of the present invention are orally-active GPIIb/llla antagonists which exhibit improved oral absorption and in vivo activity over their carboxylic acid congeners. These platelet aggregation inhibitors are useful in treating platelet-mediated thrombotic disorders such as arterial and venous thrombosis, acute myocardial infarction, reocclusion following thrombolytic therapy and angioplasty, inflammation, unstable angina, and a variety of vaso-occlusive disorders. These compounds are also useful as antithrombotics used in conjunction with fibrinolytic therapy (e.g., t-PA or streptokinase). Pharmaceutical compositions containing such compounds are also part of the present invention. DETAILED DESCRIPTION OF THE INVENTION More particularly, the present invention is directed to compounds of the following formula (I): (I) wherein M is (CH2)m, CH=CH or C≡C; A is selected from any of piperidin-2-yl, piperidin-3-yl, piperidiι -yl, CH(NH), CMe(NH) or acyl, preferably R9 is hydrogen; Rl0 is H or C(O)N(R1)YZ, wherein R1 is selected from H or cydoalkyl; R2 is selected from any of H, alkyl or acyl, preferably R2 is hydrogen; R5 is H or C(O)NHQ(CHW)rCO2R8; wherein Q is selected from CH2, CH-aryl, CH-heteroaryl, CH-substituted-heteroaryl or CH-alkyl; preferably Q is CH2, CH-substituted-heteroaryl or CH-heteroaryl; W is selected from H or N(R6)T-R7, preferably W is H when Q is CH, and N(Re)-T-R7 when Q is CH2; wherein Re is selected from any of H, alkyl or acyl, preferably RQ is hydrogen; T is selected from C(O), C(N-CN) or SO2, preferably T is C(O); R7 is selected from any of alkyl, aryl, aralkyl, alkoxy, or aminoalkyi; and Re is H or CH 2 C(0)NRιιRι 2 , preferably Re is CH2C(O)NRnRι 2l most preferably Re is CH 2 C(O)NEt2; R11 and R12 are selected from H, alkyl, or cycloalkyl, preferably Rn and R1 2 are alkyl; m is the integer 1 , 2, or 3, preferably m is 1 or 2; X is selected from any of C(O), C(O)O, C(0)NH, CH 2 , or SO2; n is the integer 1 , 2, or 3; r is 0 or 1 ; Y is selected from any of (CH 2 ) P , CH(R3)(CH2)q, (CH2)qCH(R3) I (CH(CO2 R4)CH2)q, (CH2)qCHOH or piperidine-3-carboxylic acid; with the proviso that when Y is (CH2)ρ and p is 2, X is other than C(O) or when X is C(O) then either R1 is other than H or R2 is other than H, and with the proviso that when Y is (CH(CO2R4)CH2)q is other than C(O) or CH2; p is 2 or 3; q is 1, 2, or 3, preferably, q is 1; R3 is alkyl, C2-C8 alkenyl, C2-C8 alkynyl, aryl, aralkyl or heteroaryl; R4 is H or alkyl or cycloalkyl, preferably R4 is hydrogen; Z is Cθ2CH2C(O)NRιιRι 2 ; provided that at least one of R5 and R10 is hydrogen and R5 and R10 are not hydrogen at the same time; provided that when R5 is C(O)NHQ(CHW)rCO2 R8, and Q is CH-heteroaryl or CH-substituted-heteroaryl, and Re is H, then M is CH=CH; or the enantiomer or the pharmaceutically acceptable salt thereof. Preferably, the group C(0)N(R1)YZ is attached to the ring carbon of the central azacycle at the 3- or 4-position (4-position when larger than a five- membered ring), and most preferably the 3-position. As used herein, unless otherwise noted alkyl and alkoxy whether used alone or as part of a substituent group, include straight and branched chains having 1-8 carbons. For example, alkyl radicals include methyl, ethyl, propyl, isopropyl, tr-butyl, isobutyl, sec-butyl, f-butyl, n-pentyl, 3-(2-methyl)butyl, 2- pentyl, 2-methylbutyl, neopeπtyl, n-hexyl, 2-hexyl and 2-methylpentyl. Alkoxy radicals are oxygen ethers formed from the previously described straight or branched chain alkyl groups. Cycloalkyl groups contain 5-8 ring carbons and preferably 6-7 carbons. The term "aryl", "heteroaryl" or "substituted heteroaryl" as used herein alone or in combination with other terms indicates aromatic or heteroaromatic groups such as phenyl.naphthyl, pyridyl, thienyl, furanyl, or quinolinyl wherein the substituent is an alkyl group. The term "aralkyl" means an alkyl group substituted with an aryl group. The term "acyl" as used herein means an organic radical having 2-6 carbon atoms derived from an organic acid by removal of the hydroxyl group. The compounds of the present invention may also be present in the form of a pharmaceutically acceptable salt. The pharmaceutically acceptable salt generally takes a form in which the nitrogen on the 1-piperidine (pyrrolidine, piperazine) substituent is protonated with an inorganic or organic acid. Representative organic or inorganic acids include hydrochloric, hydrobromic, hydriodic, perchloric, sulfuric, nitric, phosphoric, acetic, propionic, glycolic, lactic, succinic, maleic, fumaric, malic, tartaric, citric, benzoic, mandelic, methanesulfonic, hydroxyethanesulfonic, benezenesulfonic, oxalic, pamoic, 2- naphthalenesulfonic, p-toluenesulfonic, cyclohexanesulfamic, salicylic, saccharinic or trifluoroacetic acid. Particularly preferred compounds of the present invention include those compounds shown in Table I. Where it is noted, the letter "R" indicates the absolute configuration (Cahn-lngold-Prelog rules). TABLE I 1 3-Pyridyl Et H 2 3,4-OCH 2 OPh Et H 3 5-Bromo-3-pyridyl Et H 4 H Et NHCO 2 CH 2 Ph 5 * H Et NHCO 2 CH 2 Ph 6* H (CH 2 )s NHCC^C^Ph * Compound contains 4-piperidine-3-propenoyl N-terminus (compounds #1-4 contain 4-piperidine-3-propanoyl N-terminus). The compounds of the invention wherein Rio is H, R5 is C(0)NHQ(CHW)rC02R8, and A is piperidin-4-yl, may be prepared as shσwi in Schemes AA and AB. EnantiomericaJly-enrichθd R-(-)-nipecotic acid ethyl ester was isolated by chiral resolution of racemic material as its corresponding D-tartaric acid salt (A. M. Akker an, Rec. Trav. Chim. Pays- Bas 1951, 70, 899), and then converted to Boc-R-nipecotic acid using standard conditions (aq. sodium hydroxide, di-f-butyldicarbonate). Intermediate AA1 was prepared as detailed in provisional U.S. patent application 60-016675 (May 1, 1996) and as published (J. Rico, J. Org. Chem. 1993, 58, 7948). Standard amide bond coupling conditions using AA1, HBTU, HOBT, and Boc-R-nipecotic acid, followed by Boc removal with HCI afforded AA2. Compound AA2 was then acylated with HBTU-activated Boc- 4-piperidinepropanoic acid and the resultant methyl ester saponified with lithium hydroxide to give acid AA3. The carboxylate AA3 was then alkyiated with 2-chloro-Λ/,Λ/-diethylacetamide/triethylamine in EtOAc, and the Boc group removed with HCI to give final product #1 as its dihydrochloride salt. Compounds #2 and #3 were prepared as shown for #1; resolved β-amino ester starting materials (see AA1 experimental) were prepared as shown for AA1. SCHEME AA Compound #4 was prepared in a similar manner. Boc-R-nipecotic acid was coupled with methyl N-α-CBZ-L-diaminopropionate (prepared by MeOH HCI Fischer esterificatjon of commercially-available N-α-CBZ-L- diaminopropionic acid) and then the Boc group removed with HCI to afford AB2. In this synthetic sequence, acid AB3 was alkylated using 2-chloro-Λ/,/V- diethylacetamide/cesium carbonate in DMF, and then converted to #4 with HCI. SCHEME AB 2-Chloro-Λ/,Λ/-diethylacetamide was purchased from Aldrich Chemical Company. Chloroacetamides may be prepared in one step from 2- chloroacetyl chloride and the appropriate amine (Scheme AC; K. Krakowiak, J. Heterocydic Chem. 1989, 26, 661 ). In this procedure, 2-chloroacetyl chloride and aq. sodium hydroxide were added dropwise to a solution of amine/DCM at RT and reacted over a 1-2 h period. SCHEME AC SCHEME AD AD1 AD2 AD3 Intermediate Λ/-Boc-4-piperidinepropenoic add AD3 may be prepared as shown in Scheme AD. Alcohol AD1 was oxidized to the corresponding aldehyde AD2 using standard Swem conditions (oxalyl chloride DMSO). AD2 was converted to the olefinic ester using the Wittig reagent in dichloromethane. This ester was then saponified to the add in sodium hydroxide to afford AD3. To prepare compound #5, AD3 was coupled with AB2 as described for compound #4 (HBTU/HOBT) and carried forward to final product as shown in Scheme AB. 99/218 To prepare the compounds where A is pyrrolidin-2-yl or pyrrolidin-3-yl, intermediate AA2 was acylated with 3-(N-Boc-pyrrolidinyl)propionic add to produce the acylated derivative using the HBTU acylation procedure. 3-(N- Boc-pyrrolidinyl)propionic add was synthesized using the methods described in US Patent 4,002,643. Using these procedures, N-Boc- pyrrolecarboxaldehyde (two or three substitution) was treated with sodium hydride/diethyl cyanomethyl-phosphonate in DME to give 3-(N-Boc- pyrrole)acrylonitrile, which was reduced using standard hydrogenolysis conditions (H 2 , platinum oxide) to afford 3-(N-Boc-pyrrolidinyl)propionitrile. The nitrile was then hydrolyzed with aqueous sodium hydroxide to give 3-(N- Boc-pyrrolidinyl)propionic add (two or three substitution). To prepare the compounds where A is piperazin-1-yl, intermediate AA2 was acylated with acryloyl chloride/NMM as published (S. G. Giibreath, J. Am. Chem. Soc. 1988, 110, 6172), and the corresponding acrytamide then treated with the appropriate piperazine (e.g. N-methytpiperazine) in refluxing ethanol to give the piperazine product. To prepare the compounds where A is N-alkyl-piperidine (R© = alkyl), compound #1, for example, was treated with aldehyde/sodium cyanoborohydride in ethanol to give the N-alkytpiperidine. Formamidinopiperidines were prepared by treating ompound #1, for example, with ethyl formimidateΗCI in ethanol; the corresponding acetamidinopiperidines were prepared using S-2-naphthylmethyl thioacetimidate«HCI in ethanol (B. Shearer, Tetrahedron Lett. 1997, 38, 179). To prepare the compounds where A is NHR ∑ , intermediate AA2 was acylated with N-Boc-R 2 -aminohexanoic add, for example, using the standard HBTU coupling conditions dted for example 1. Compounds where M is ethynyl were prepared by displacement of N- Boc-4-methanesulfonyloxypiperidine with potassium ethyl propiolate (potassium carbonate/ethyl propiolate) to give methyl N-Boc-4-piρeridineprop- 3-ynoate (T. Jeffery, Tetrahedron Lett. 1989, 30, 2225). This ester was then saponified to the corresponding carboxylic add and coupled with intermediate AA2 using HBTU. Compounds where R10 is C(O)NR(1)YZ and R5 is H are prepared according to the method described in Scheme AA using an appropriately substituted boc-R-nipecotic add as the starting material. To prepare the pharmaceutical compositions of this invention, one or more compounds of formula (I) or salt thereof of the invention as the active ingredient, is intimately admixed with a pharmaceutical carrier according to conventional pharmaceutical compounding techniques, which carrier may take a wide variety of forms depending of the form of preparation desired for administration, e.g., oral or parenterat such as intramuscular. In preparing the compositions in oral dosage form, any of the usual pharmaceutical media may be employed. Thus, for liquid oral preparations, such as for example, suspensions, elixirs and solutions, suitable carriers and additives indude water, glycols, oils, alcohols, flavoring agents, preservatives, coloring agents and the like; for solid oral preparations such as, for example, powders, capsules, caplets, gelcaps and tablets, suitable carriers and additives indude starches, sugars, diluents, granulating agents, lubricants, binders, disintegrating agents and the like. Because of their ease in administration, tablets and capsules represent the most advantageous oral dosage unit form, in which case solid pharmaceutical carriers are obviously employed. If desired, tablets may be sugar coated or enteric coated by standard techniques. For parenterals, the carrier will usually comprise sterile water, through other ingredients, for example, for purposes such as aiding solubility or for preservation, may be induded. Injectable suspensions may also be prepared, in which case appropriate liquid carriers, suspending agents and the like may be employed. The pharmaceutical compositions herein will contain, per dosage unit, e.g., tablet, capsule, povΛJer, injection, teaspoonful and the like, an amount of the active ingredient necessary to deliver an effective dose as described above. The pharmaceutical compositions herein will contain, per unit dosage unit, e.g., tablet, capsule, powder, injection, suppository, teaspoonful and the like, of from about 0.03 mg to 100 mgkg (preferred 0.1-30 mg kg) and may be given at a dosage of from about 0.1-300 mg kg/day (preferred 1-50 mg kg day). The dosages, however, may be varied depending upon the requirement of the patients, the severity of the condition being treated and the compound being employed. The use of either daily administration or post-periodic dosing may be employed. 99/21832 BIOLOGY The glycolamide ester compounds of the present invention are orally- active GPIIb/llla antagonists which show improved oral absorption and in vivo adivity over their carboxylic add congeners. For instance, compound #4 exhibited >240 min duration in vivo (see Table III) whereas its carboxylic add congener exhibited 180 min duration at the same oral dose. The compounds interrupt binding of fibrinogen to platelet glycoprotein llb/llla (GPIIb/llla) and thereby inhibit platelet aggregation. Such compounds are, therefore, useful in treating platelet-mediated thrombotic disorders such as arterial and venous thrombosis, acute myocardial infarction, reocdusion following thrombolytic therapy and angioplasty, and a variety of vaso-ocdusive disorders. Because the final, common pathway in normal platelet aggregation is the binding of fibrinogen to activated, exposed GPIIb llla, inhibition of this binding represents a plausible antithrombotic approach. The receptor is activated by stimuli such as ADP, collagen, and thrombin, exposing binding domains to two different peptide regions of fibrinogen: α-chain Arg-Gly-Asp (RGD) and γ- chain 400-411. As demonstrated by the results of the pharmacological studies described hereinafter, the compounds of the present invention show the ability to block fibrinogen binding to isolated GPIIb lla (ICso's 0.0006- 0.005 μM), inhibit platelet aggregation in vitro in the presence of a various of platelet stimuli (ICso's 0.14-1.1 μM vs. thrombin), and furthermore, inhibit ex vivo platelet aggregation in animal models. IN VITRO SOLID PHASE PURIFIED GLYCOPROTEIN IIB/IIIA BINDING ASSAY. A 96 well lmmulon-2 microtiter plate (Dynatech-lmmulon) is coated with 50 μl well of RGD-affinity purified GPIIb llla (effective range 0.5-10 μg mL) in 10 mM HEPES, 150 mM NaCI, 1 mM at pH 7.4. The plate is covered and incubated overnight at 4°C. The GPIIb/lla solution is discarded and 150 μl of 5% BSA is added and incubated at RT for 1-3 h. The plate is washed extensively with modified Tyrodes buffer. Biotinylated fibrinogen (25 μl/well) at 2 x final concentration is added to the wells that contain the test compounds (25 μl well). The plate is covered and incubated at RT for 2-4 h. Twenty minutes prior to incubation completion, one drop of Reagent A (Veda Stain ABC Horse Radish Peroxidase kit, Vector Laboratories, Inc.) and one 99/21 drop Reagent B are added with mixing to 5 mL modified Tyrodes buffer mix and let stand. The ligand solution is discarded and the plate washed (5 x 200 μl/well) with modified Tyrodes buffer. Veda Stain HRP-Biotin-Avidin reagent (50 μl/well, as prepared above) is added and incubated at RT for 15 min. The Vecta Stain solution is discarded and the wells washed (5 x 200 μl/well) with modified Tyrodes buffer. Developing buffer (10 mL of 50 mM dtrate/phosphate buffer @ pH 5.3, 6 mg o-phenylenediamine, 6 μl 30% H2O2; 50 μl/well) is added and incubated at RT for 3-5 min, and then 2Λ H2SO4 (50 μl well) is added. The absorbance is read at 490 nM The results are shown in Tables II. IN VITRO INHIBITION OF THROMBIN-INDUCED GEL-FILTERED PLATELET AGGREGATION ASSAY. The percentage of platelet aggregation is calculated as an increase in light transmission of compound-treated platelet concentrate vs. control-treated platelet concentrate. Human blood is obtained from drug free, normal donors into tubes containing 0.13W sodium dtrate. Platelet rich plasma (PRP) is collected by centrifugation of whole blood at 200 x g for 10 min at 25°C. The PRP (5 mL) is gel filtered through Sepharose 2B (bed volume 50 mL), and the platelet count is adjusted to 2x10 7 platelets per sample. The following constituents are added to a siliconized cuvette: concentrated platelet filtrate and Tyrode's buffer (0.14M NaCI, 0.0027W KCI, 0.012M NaHCO3, 0.76 mM Na 2 HPO4, 0.0055M glucose, 2 mg mL BSA and 5.0mM HEPES @ pH 7.4) in an amount equal to 350 μl, 50 μl of 20 mM caldum and 50 μi of the test compound. Aggregation is monitored in a BIODATA aggrego eter for the 3 min following the addition of agonist (thrombin 50 μl of 1 unit/mL). The results are shown in Tables II. TABLE II In Vitro Results Fibrinogen Binding Platelet Aggregation* Compound # % Inn. (50 uM) ICsg (uM) % Inn. (50uM) ICgn (uM) 1 100% 0.0007 100% 0.14 2 100% 0.005 100% 1.1 3 100% 0.0009 100% 0.19 4 100% 0.0020 100% 0.29 5 100% 0.0097 100% 0.27 6 100% 0.0025 100% 0.51 ' Thrombin-induced aggregation of gel-filtered platelets. NT = not tested. EX VIVO DOG STUDY Adult mongrel dogs (8-13 kg) were anesthetized with sodium pentobarbital (35 mg/kg, i.v.) and artificially respired. Arterial blood pressure and heart rate were measured using a Millar catheter-tip pressure transducer inserted in a femoral artery. Another Millar transducer was placed in the left ventride (LV) via a carotid artery to measure LV end diastdic pressure and indices of myocardial contractility. A lead II electrocardiogram was recorded from limb electrodes. Catheters were placed in a femoral artery and vein to sample blood and infuse drugs, respectively. Responses were continuously monitored using a Modular Instruments data aquisition system. Arterial blood samples (5-9 ml) were withdrawn into tubes containing 3.8% sodium citrate to prepare platelet rich plasma (PRP) and to determine effects on coagulation parameters: prothrombin time (PT) and activated partial thrombopiastin time (APTT). Separate blood samples (1.5 ml) were withdrawn in EDTA to determine hematocrit and cell counts (platelets, RBC's and white cells). Template bleeding times were obtained from the buccal surface using a symplate indsion devise and Whatman filter paper. Aggregation of PRP was performed using a BioData aggregometer. Aggregation d whole blood used a Chrondog impedance aggregometer. PT and APTT were determined on either a BioData or ACL 3000+ coagulation analyser. Cells were counted with a Sysmex K-1000. Compounds were solubilized in a small volume d dimethylformamide (DMF) and diluted with saline to a final concentration of 10% DMF. Compounds were administered by the intravenous route with a Harvard infusion pump. Doses was administered over a 15 min interval at a constant rate of 0.33 ml/min. Data were obtained after each dose and in 30 min intervals following the end of drug administration. Oral doses were administered as aqueous solutions via syringe. Compounds caused marked inhibition d ex vivo platelet aggregation responses. Thus, in whole blood, the compounds inhibited cdlagen- stimulated (or ADP) aggregation in doses d 0.1-10 mg kg with marked inhibition d collagen stimulated platelet ATP release. In PRP, the compounds also inhibited collagen stimulated platelet aggregaton with marked adivity at 0.1-10 mg/kg. Compounds had no measurable hemodynamic effed in doses up to 1 mg/kg, iv. The drugs produce an increase in template bleeding time at 0.1-1 mg/kg with rapid recovery post treatment. No effeds on coagulation (PT or APTT) were observed during treatment and platelet white and RBC counts were unchanged at any dose d the compounds. The results indicate that the compounds are broadly effective inhibitors d platelet aggregation ex vivo (antagonizing both collagen and ADP pathways) following iv administration of doses ranging from 0.3-1.0 mg/kg or 3 mg/kg orally. The antiaggregatory effeds are accompanied by increases in bleeding time at the higher doses. No other hemodynamic or hematologic effeds are observed. The results are shown in Table III. TABLE III Ex Vivo Dog Study Results Intravenous Dosing Oral Dosing CrτiDd # Dose Duration* Dose Duration* 1 0.3 mpk 60 min 3 mpk >180 min 2 1.0 mpk 120 min 3 mpk 150 min 3 NT NT 3 mpk 90 min 4 0.1 mpk 60 min 3 mpk >240 min 5 0.1 mpk 60 min 1 mpk >240 min 6 NT NT 1 mpk 150 min * Indicates duration d >50% inhibition d collagen-induced ex vivo platelet aggregation. NT = not tested. EXAMPLES Proteded amino adds were purchased from Aldrich Chemical or Bachem Bioscience Inc. N-α-CBZ-L-diaminopriopionic add was purchased from Fluka. Enantiomerically-enriched nipecotic add ethyl ester were isolated by chiral resolution of racemic material as published (A. M. Akkerman, Rec. Trav. Chim. Pays-Bas 1951, 70, 899). All other chemicals were purchased from Aldrich Chemical Company, Inc. High field 1 H NMR spectra were recorded on a Bruker AC-360 spectrometer at 360 MHz, and coupling constants are given in Herz. Melting points were determined on a Mel-Temp II melting pdrrt apparatus and are uncorreded. Microanalyses were performed at Robertson Micrdit Laboratories, Inc., Madison, New Jersey and are expressed in percentage by weight of each element per total molecular weight. In those cases where the produd is obtained as a salt, the free base is obtained by methods known to those skilled in the art e.g. by basic ion exchange purification. Nudear magnetic resonance (NMR) spectra for hydrogen atoms were measured in the indicated solvent with tetramethylsilane (TMS) as the internal standard on Bruker A -360 (360 MHz), AM-400 (400 MHz), or AT-300 (300 MHz) spectrometer. The values are expressed in parts per million down field from TMS. The mass spectra (MS) were determined on a Finnigan 3300 spedrometer (methane), using desorption chemical ionization techniques. Unless otherwise noted, the materials used in the examples were obtained from readily available commercial suppliers or synthesized by standard methods known to anyone skilled in the art of chemical synthesis. The substituent groups, which vary between examples, are hydrogen unless otherwise noted. In the Examples and throughout this application, the following abbreviations have the meanings redted hereinafter. Bn or Bzl = Benzyl Boc = t-Butoxycarbonyl BOC-ON = 2-(f-Butoxycarbonyloxyimino)-2-phenylacetonitrile BOP-CI = Bis(2-oxo-3-oxazolidinyl)phosphinic chloride CBZ = Benzyloxycarbonyl CP = compound DCE = 1,2-Dichloroethane DCM = Dichloromethane DIC = Diisopropylcarbodiimide DIEA = Diisopropylethylamine DMAP = 4-Dimethylaminopyridine DMF = N, N-Dimethylformamide EDC = Ethyl dimethylaminopropylcarbodiimide EDTA = Ethylenediaminetetraacetic add Et2θ = Diethyl ether HBTU = 2-(1 H-Benzotriazde-1 -yl)-1 , 1 ,3,3-tetramethyluronium hexafluorophosphate HOBT = Hydroxybenzotriazole -Pr = Isopropyl MPK = milligrams per kilogram NMM = N-Methylmorphoiine Nip = Nipecotyl (unless noted otherwise, racemic at 3-position) NT = not tested PPT = predpitate PTSA = p-Tduenesulfonic add RT = room temperature TFA = Trifluoroacetic add Z = Benzyloxycarbonyl The following examples describe the invention in greater detail and are intended to illustrate the invention, but not to limit it. Methyl (S)-3-amino-3-(3-pyridv0 prodonate • 2HCI (AA1) A mixture d 3-pyridinecarboxaldehyde (0.47 rnol), EtOH (100 mL), NH 4 OAc (0.47 mol), and malonic add (0.70 mol) was heated at reflux for 6 h, cooled, and filtered. The white solid was washed with EtOH and MeOH and dried (E. Profft, J. Prakt. Chem. 1965, 30, 18). This solid was dissdved in 2:1 acetone water (360 mL), treated with triethylamine (0.72 mol) and phenylacetyl chloride (0.36 mol), and stirred for 22 h. The mixture was evaporated and the residue dissolved in water (500 mL) and adjusted to pH 12 (1 N NaOH). The aqueous layer was adjusted to pH 2 (cone. HCI), extracted with Et 2 O, and evaporated to a white foam. The foam was purified by silica gel chromatography (10% MeOH/DCM) to give racemic 3- phenylacetamido-3-(3-pyridyl)propionic add. A solution d this compound (0.22 mol) in water (600 mL) at RT was adjusted to pH 7.5 using KOH (3.0 N) and treated with penidllin amidase (91520 units, Sigma). This mixture was stirred for 47 h, acidified to pH 1 with HCI (cone), and the resultant ppt filtered through Celite The filtrate was extracted with Et2θ (3x300 mL), concentrated in vacuo, and treated with MeOH/conc. NH4OH (9:1). This product-containing solution was purified by silica gel chromatography (eluent DCM/MeOH NH4θH, 78:18:4) to give (S)-3-phenylacetamido-3-(3- pyridyl)propionic add ammonium salt (19.5 g, 58%). This produd was treated with HCI (6.0 N, 292 mL), heated at reflux for 5 h, coded to RT, and extracted with Et2θ (3x200 mL). The aqueous layer was adjusted to pH 12, concentrated in vacuo, and the resultant sdid triturated with MeOH (2x300 mL). This solution was evaporated to give ca. 14 g sodium salt This material was treated with MeOH (500 mL), 2,2-dimethoxypropane (44 mL), and HCI (4 N in dioxane, 84 mL), and stirred for 90 h at RT. This mixture was filtered and the filtrate concentrated in vacuo. The resultant off-white solid was triturated with Et2 (2 x 150 mL) and dried to give compound AA1 (16.7 g, 96% ee) as a white, amorphous sdid. EXAMPLE 1 N-3-(4-Piperidinepropionyl)-R-(-)-nipecotyl-f(S)-3-amino-3-(3-pyridyl)l propionic add 2-<Oiethylamino)-2-oxoethyl ester * 2HCI (1) To a mixture of AA1 • 2HCI (2.0 g, 8.0 mmol), MeCN (120 mL), Boc-R- nipecotic add (1.8 g), and HOBT (1.1 g) at 5°C was added NMM (2.6 mL) and HBTU (3.5 g). The mixture was stirred for 20 h, diluted with sat'd ammonium chloride (25 mL), and the MeCN evaporated. This mixture was diluted with EtOAc (120 mL) and the layers separated. The organic layer was dried (sodium sulfate) and evaporated to give a tan foam. The foam was dissolved in dioxane (35 mL) and anisde (1 mL), treated with HCI (25 mL, 4 N in dioxane), and stirred at RT for 2.5 h. The resultant mixture was evaporated and the white foam triturated with Et 2 0 (50 mL) to give 2.8 g AA2. A mixture d compound AA2, MeCN (120 mL), HOBT (1 g), and HBTU (3.3 g) at 5°C was treated with NMM (2.5 mL) and N-Boc-4-piperidinepropionic add (1.9 g) and stirred for 4.5 h. The reaction was diluted with sat'd ammonium chloride (30 mL), and the MeCN evaporated. This mixture was diluted with EtOAc (120 mL) and the layers separated. The organic layer was dried (sodium sulfate) and evaporated to give a foam. The foam was purified by silica gel chromatography (0.5% NH4θH/7%EtOH DCM) to afford a white foam (2.1 g). This foam was dissolved in THF (25 mL), cooled to 5 β C, and treated with aq. lithium hydroxide (0.25 g in 35 mL water). The readion was stirred for 2 h, addified with dtric acid (0.6 g), and extraded with CHCb (3x50 mL). The combined organics were dried (sodium sulfate) and evaporated to afford AA3 as a white foam (1.9 g). Compound AA3 (1.0 g, 1.9 mmol) was dissolved in EtOAc (50 mL) and triethylamine (0.3 mL) and treated with sodium iodide (0.09 g) and then 2-chloro-N,/V-diethylacetamide (0.60 mL). This mixture was stirred for 22 h, diluted with sat'd ammonium chloride (30 mL) and EtOAc (100mL), and the layers separated. The organic layer was dried (sodium sulfate) and evaporated to give a foam. The foam was purified by silica gel chromatography (0.5% NH θH/8%EtOH/DCM) to afford a glass (0.56 g). The glass was dissolved in dioxane (25 mL) and anisole (0.5 mL), treated with HCI (15 mL, 4 N in dioxane), and stirred at RT for 4 h. The resultant mixture was evaporated and the white foam triturated with Et 2 O (50 mL) to give 1 as a white amorphous sdid (0.23 g): mp 93-100 β C. 1 H NMR (DMSO-dβ) δ 8.9 (m, 3 H), 8.6 (m, 2 H), 8.5 (t, 1 H), 8.0 (t, 1 H), 5.4 (m, 1 H), 4.7 (s, 2 H), 4.2 (m, 1 H), 3.7 (m, 2 H), 3.2 (q, 2 H), 3.1 (q, 2 H), 2.8 (m, 4 H), 2.6 (m, 2 H), 2.3 (m, 3 H), 1.2-2.0 (m, 13 H), 1.1 (t, 3 H), 0.9 (t, 3 H); MS m/e 530 (MH + ). Anal, calcd. for C28H43N5O5 • 2.3 HCI • 1.3 Dioxane (729.68): C, 52.67; H, 7.69; N, 9.59; Cl, 11.18. Found: C, 52.83; H, 7.99; N, 9.02; Cl, 11.53. EXAMPLE 2 N-3-(4-Piperidinepropionyl)-R- -)-nipecotyl-[(S)-3-amino-3- 3.4- methylenedioxyphenvM prodonic add 2-(Diethylamino)-2-oxoethyl ester » HCI (2) Compound 2 was prepared as described in example 1 starting with methyl (S)-3-amino-3-(3,4-methylenedioxyphenyl)propionate • HCI (2.2 g), and isdated as a white powder (0.70 g): 1 H NMR (CDCb) δ 9.2 (m, 1 H), 8.8 (m, 1 H), 8.4 (d, 1 H), 6.8 (m, 3 H), 5.91 (s, 2 H), 5.4 (m, 1 H), 4.8 (m, 2 H), 4.3 (m, 1 H), 3.7 (m, 1 H), 3.1-3.5 (m, 5 H), 2.6-3.0 (m, 4 H), 2.4 (m, 3 H), 1.6-2.0 (m, 7 H), 1.2-1.5 (m, 7 H), 1.1 (q, 3 H), 0.9 (t, 3 H); MS m e 573 (MH + ). Anal, calcd. for C30H44N4O7 • 1.7 TFA • 0.5 H ∑ O (775.55): C, 51.73; H, 6.07; N, 7.22; F, 12.49; KF, 1.16. Found: C, 51.75; H, 6.23; N, 7.13; F, 12.35; KF, 1.12. EXAMPLE 3 N-3- 4-Piperidineprodcxiyl)-R-(-)-nipecotyl fS 3-amino-3-(5-bromo-3- pyridvM propionic add 2- Diethylamino)-2-oxoethyl ester « 2HCI (3) Compound 3 was prepared as described in example 1 starting with methyl (S)-3-amino-3-(5-bromo-3-pyridyl)propionate • 2HCI (2.9 g), and isdated as a white foam (0.40 g): mp 63-69°C. 1 H NMR (DMSO-cfe) δ 8.8 (m, 3 H), 8.55 (s, 1 H), 8.48 (s, 1 H), 8.4 (m, 1 H), 8.0 (m, 1 H), 5.2 (m, 1 H), 4.72 (s, 2 H), 3.9 (m, 1 H), 3.2 (m, 6 H), 2.9 (m, 2 H), 2.7 (m, 2 H), 2.2 (m, 2 H), 1.9 (m, 3 H), 1.2-1.8 (m, 12 H), 1.1 (t 3 H), 1.0 (t, 3 H); MS m/e 608 and 610 (MH + ). Anal, calcd. for C 2 8H42BrN5θ 5 • 2.1 HCI • 1.0 H 2 O • 0.5 Dioxane (747.23): C, 48.22; H, 6.76; N, 9.37; Cl, 9.96. Found: C, 48.01; H, 6.97; N, 9.13; Cl, 10.28. EXAMPLE 4 N-3-(4-Piperidinepropionyl)-R-(-)nipecotyl-f(S)-2-benzyloxycarbonylamino-3- aminolpropionic add 2- Diethylamino)-2-oxoethyl ester • HCI (4) To a mixture of AB1 • 2HCI (12.2 g, 42 mmol), MeCN (300 mL), Boc-R- nipecotic add (9.7 g), and HOBT (5.8 g) at 5 β C was added NMM (9.3 mL) and HBTU (15.9 g). The mixture was stirred for 24 h at 5 β C, diluted with sat'd ammonium chloride (50 mL), and the MeCN evaporated. This mixture was diluted with EtOAc (300 mL) and the layers separated. The organic layer was washed with sat'd sodium bicarbonate (50 mL), dried (magnesium sulfate), evaporated, and purified by silica) gel chromatography (1.5% MeOH/DCM) to give a white foam (14.8 g). The foam was dissolved in dioxane (30 mL), treated with HCI (30 mL, 4 Λ7 in dioxane), and stirred at RT for 2 h. The resultant mixture was evaporated and the white foam triturated with Et ∑ O (50 mL) to give AB2 (13 g). A mixture d compound AB2 (6.3 g), MeCN (200 mL), HOBT (2.1 g), and HBTU (5.9 g) at 5°C was treated with NMM (5.2 mL) and N-Boc-4-piperidinepropionic add (4.0 g) and stirred for 22 h. The reaction was diluted with sat'd ammonium chloride (40 mL), and the MeCN evaporated. This mixture was diluted with EtOAc (120 mL) and the layers separated. The organic layer was washed with sat'd sodium bicarbonate (30 mL), dried (magnesium sulfate), evaporated, and purified by silical gel chromatography (2.5% MeOH/DCM) to give a foam (7.7 g). 2.5 g d this foam was dissolved in THF (15 mL), cooled to 5*C, and treated with aq. lithium hydroxide (0.17 g in 30 mL water). The reaction was stirred for 2.5 h, addified with acetic add (1 mL), and extraded with CHCb (3x50 mL). The combined organics were dried (magnesium sulfate) and evaporated to afford AB3 as a white foam (2.1 g). Compound AB3 (1.0 g, 1.9 mmol) was dissdved in DMF (20 mL), water (5 mL), and cesium carbonate (1.0 g), and treated with 2-chloro-Λ,Λ-diethylacetamide (2.1 mL). This mixture was heated at 75°C for 22 h, coded to RT, concentrated in vacuo, and diluted with DCM (60 mL). This mixture was washed with water (25 mL), dried (magnesium sulfate), and evaporated to give a foam. The foam was purified by silica gel chromatography (4%MeOH/DCM) to afford a glass (1.6 g). The glass was treated with HCI (10 mL, 4 N in dioxane), and stirred at RT for 1.5 h to give a ppt. The HCI was decanted and the ppt triturated with Et^ (50 mL) and dried to afford 4 as a white amorphous solid (0.95 g): mp 57-61 β C. 1 H NMR (DMSO-dβ) δ 8.9 (m, 1 H), 8.6 (m, 1 H), 8.1 (m, 1 H), 7.7 (t, 1 H), 7.3 (m, 5 H), 5.05 (s, 2 H), 4.8 (m, 2 H), 4.2 (m, 1 H), 3.8 (m, 1 H), 3.1-3.4 (m, 6 H), 2.7 (m, 3 H), 2.3 (m, 2 H), 1.2-1.9 (m, 16 H), 1.1 (t, 3 H), 1.0 (t, 3 H); ); MS m/e 602 (MH + ). Anal, calcd. for C31H47N5O7 • 1.2 HCI • 1.7 H 2 O (676.12): C, 55.07; H, 7.69; N, 10.36; Cl, 6.29. Found: C, 54.86; H, 7.72; N, 10.39; Cl, 6.11. N-f-Butoxycarbonyl-4-piperidine-3-properκ>ic add (AD3) To a solution d oxalyl chloride (24.8 mL, 50 mmol) in DCM (200 mL) at -78 β C was added DMSO (7.0 mL) dropwise. The mixture was stirred for 30 min, treated with AD1 (8.2 g, 38 mmol), and stirred for 2 h. Triethylamine (31.7 mL) was added dropwise, the mixture was warmed to RT, and the mixture diluted with water (30 mL). The layers separated; the organic layer was washed with safd ammonium chloride (30 mL) and safd sodium chloride (30 mL), dried (magnesium sulfate), evaporated, and purified by silica gel chromatography (20% EtOAc/hexane) to give AD2 (7.3 g, 34 mmol) as a white solid. A solution d ethyl 2-(triphenytphosphoranylidene)acetate (13.1 g, 38 mmol) and DCM (40 mL) at 5°C was treated with AD2 (7.3 g), warmed to RT, stirred for 2.5 h, and evaporated to dryness. This solid was treated with pentane (50 mL), and triphenylphosphine oxide removed by filtration. The pentane solution was concentrated and the solid purified by silica gel chromatography (10% EtOAc/hexane) to afford a glass (8.4 g). The glass was dissolved in EtOH (60 mL) and this solution treated with water (60 mL) and sodium hydroxide (59 mL, 1.0 N) at RT. The mixture was stirred for 4 h, addified with dtric acid (8 g), and extracted with DCM (3x100 mL). The combined organics were dried (magnesium sulfate) and evaporated to give AD3 (7.5 g) as a white sdid. MS m/e 256 (MH + ). EXAMPLE 5 N-3-(4-Piperidineproρenoyl)-R-(-)nipecotyl (S)-2-benzyloxycarbonylamino-3- aminolpropionic add 2-(Diethylamino)-2-oxoethyl ester » HCI (5 Intermediate AD3 (8.5 mmol) and intermediate AB2 (8.5 mmol) were coupled using HBTU/HOBT and the produd carried forward to give 5 as described in example 4. Compound 5 was isdated as a white powder (1.6 g): mp 42- 45 β C. MS m/e 600 (MH + ). Anal, calcd. for C 3 1H45N5O7 • 1.0 HCI • 2.0 H^ (672.22): C, 55.39; H, 7.50; N, 10.42; Cl, 5.27. Found: C, 55.62; H, 7.37; N, 10.44; Cl, 5.27. EXAMPLE 6 N-3-(4-PiperidinepropenoylV4 -)nipeα3tyl fS)-2-benzyloxycar^ aminolprodonic add 2-(Piperidino)-2-oxoethyl ester - HCI (6) Intermediate AD3 (6.2 mmol) and the piperidide derivative of intermediate AB2 (6.2 mmol) were coupled using HBTU/HOBT and the produd carried forward to give 6 as described in example 4. Compound 6 was isdated as a white powder (0.94 g): mp 52-56'C. MS me 612 (MH + ). Anal, calcd. for C32H45N5O7 • 1.0 HCI • 2.6 H 2 0 (695.04): C, 55.30; H, 7.42; N, 10.08; Cl, 5.10. Found: C, 55.05; H, 7.39; N, 9.86; Cl, 5.05.

Claims: 99/21832 WE CLAIM: 1. A compound represented by the general formula (I): (I) wherein M is (CH2)m, CH=CH or C≡C; A is seleded from any d piperidin-2-yl, piperidin-3-yl, piperidin-4-yl, piperazin-1-yl, pyrrdidin-2-yl, pyrrolidin-3-yl, NHR2 or ^ wherein Rg is sdeded from any d H, alkyl, CH(NH), CMe(NH) or acyl; Rio is H or C(O)N(R1)YZ, wherein R1 is seleded from H or cydoalkyl; R2 is seleded from any d H, alkyl or acyl; R5 is H or C(0)NHQ(CHW)rC02R8; wherein Q is seleded from CH2, CH-aryl, CH-heteroaryl, CH-substituted-heteroaryl or CH-aJkyl; W is seleded from H or N(Rβ)T-R7; wherein Re is seleded from any d H, alkyl or acyl; T is seleded from C(O), C(N-CN) or SO2; R7 is seleded from any d alkyl, aryl, aralkyl, alkoxy, or aminoalkyi; and Re is H or CH 2 C(0)NRnRι 2 , wherein Rn and R1 2 are seleded from H, alkyl, or cycloalkyl; m is the integer 1 , 2, or 3; X is seleded from any of C(O), C(0)O, C(O)NH, CH2, or SO2; n is the integer 1 , 2, or 3; r is 0 or 1 ; Y is seleded from any d (CH 2 ) P , CH(R3)(CH 2 )q, (CH 2 )qCH(R3), (CH(Cθ2 R4)CH2)q, (CH2)qCHOH or piperidine-3-carboxylic add; with the proviso that when Y is (CH ∑ Jp and p is 2, X is other than C(O) or when X is C(O) then either R1 is other than H or R2 is other than H, and with the proviso that when Y is (CH(CO2R4)CH 2 )q X is other than C(O) or CH2; p is 2 or 3; q is 1, 2, or 3; R3 is alkyl, C2-C8 alkenyl, C2-C8 alkynyl, aryl, aralkyl or heteroaryl; R4 is H or alkyl or cydoalkyl; Z is Cθ2CH 2 C(0)NRnRι 2 ; provided that at least one of R5 and R10 is hydrogen and R5 and R10 are not hydrogen at the same time; provided that when R5 is C(0)NHQ(CHW)rCθ2 Rβ, and Q is CH- heteroaryl or CH-substituted-heteroaryl, and Rβ is H, then M is CH=CH; or the enantiomer or the pharmaceutically acceptable salt thered. 2. The compound d daim 1 wherein Rβ is CH 2 C(0)NRnRi 2 . 3. The compound d daim 1 wherein the group C(O)N(Rι)YZ is attached at the 3- or 4- position d the central azacyde. 4 The compound of daim 1 wherein the group C(O)N(Rι)YZ is attached at the 3- position of the central azacycle. 5. The compound d daim 1 wherein R5 is C(0)NHQ(CHW)rCθ2Rβ. 6. A compound of daim 1 of the formula: (I) wherein M is (CH2)m, CH=CH or C≡C; A is seleded from any of piperidin-2-yl, piperidin-3-yl, piperidin- -yl, piperazin-1-yl, pyrrolidin-2-yl, pyrrolidin-3-yl, CH(NH), CMe(NH) or acyl; Rlθ is H or C(O)N(R1)YZ, wherein R1 is seleded from H or cydoalkyl; R2 is H; R5 is H or C(0)NHQ(CHVv C02R8; wherein Q is seleded from CH2, CH-heteroaryl or CH-substituted-heteroaryl; W is seleded from H or N(Rβ)T- R7; wherein Rβ is H; T is C(O); R7 is selected from any d alkyl, aryl, aralkyl, alkoxy, or aminoalkyi; and Rβ is H or CH 2 C(O)NRnRι 2 ; wherein Rn and R 12 are alkyl; m is the integer 1 or 2; X is seleded from any of C(O), C(O)O, C(O)NH, CH 2l or SO2; n is the integer 1, 2, or 3; r is O or l; Y is seleded from any d (CH 2 ) P , CH(R3)(CH 2 )q, (CH2)qCH(R3), (CH(Cθ2 R4)CH2)q, (CH2)qCHOH or piperidine-3-carboxylic add; with the proviso that when Y is (CH2)p and p is 2, X is other than C(O) or when X is C(O) then either R1 is other than H or R2 is other than H, and with the proviso that when Y is (CH(CO2R4)CH 2 )q X is other than C(O) or CH2; p is 2 or 3; q is 1; R3 is alkyl, C2-C8 alkenyl, C2-C8 alkynyl, aryl, aralkyl or heteroaryl; R4 is H; Z is Cθ2CH 2 C(O)NRnRι 2 ; provided that at least one d R5 and R10 is hydrogen; provided that when R5 is C(0)NHQ(CHW)rC02 Rβ, and Q is CH- heteroaryl or CH-substituted-heteroaryl, and Rβ is H, then M is CH-CH; or the enantiomer or the pharmaceutically acceptable salt thered. 7. The compound d daim 6 wherein Rβ is CH 2 C(0)NRnRι 2 . 8. The compound of daim 6 wherein the group C(O)N(R 1 )YZ is attached at the 3- or 4- position of the central azacyde. 9. The compound of daim 6 wherein the group C(0)N(R 1 )YZ is attached at the 3- position d the centrtal azacyde. 10. The compound of daim 6 wherein R5 is C(0)NHQ(CHW) r C02Rβ. 11. The compound of daim 1 wherein: R5 is H or C(O)NHQ(CHW)rCθ2Rβ; wherein Q is seleded from CH2, CH-heteroaryl or CH-substituted-heteroaryl; W is seleded from H or N(Rβ)T- R7; wherein R6 is H; T is C(O); R7 is seleded from any d alkyl, aryl, aralkyl, alkoxy, or aminoalkyi; and Rβ is CH 2 C(O)NRnRι 2 ; herein Rn and Rι 2 are alkyl. 12. The compound of daim 1 d the formula: wherein R11 and R12 are alkyl or taken together are (CH2)s; R13 is selected from H, 3-pyridyl, 3,4-OCH2Ph and 3-bromo-3-pyridyl; and R14 is seleded from H, and NHCC^Ph 13. The compound d daim 1 , seleded from any of. N-3-(4-Piperidinepropionyl)-R-(-)-nipecotyl-{(S)-3-amino-3-(3-pyridyl)] propionic add 2-(Diethylamino)-2-oxoethyl ester • 2HCI, N-3-(4-Piperidinepropionyl)-R-(-)-nipecotyl-[(S)-3-amino-3-(3,4- methylenedioxyphenyl)] propionic add 2-(Diethylamino)-2-oxoethyl ester 2HCI, N-3-(4-Piperidinepropionyl)-R-(-)-nipecotyl-[(S)-3-amino-3-(5-bromo-3- pyridyl)] propionic add 2-(Diethylamino>-2-oxoethyl ester • 2HCI, N-3-<4-Piperidinepropionyl)-R-(-)nipecotyl-{(S)-2-benzyloxycarbonylamino-3- aminojpropionic add 2-(Diethylamino)-2-oxoethyl ester • HCI, N-f-Butoxycarbonyl-4-piperidine-3-propenoic add, N-3-(4-Piperidinepropenoyl)-R-(-)nipecc^-{(S)-2-beruεyloxyrarbonylamino-3- aminojpropionic add 2-{Diethylamino)-2-oxoethyl ester • HCI, and N-3-(4-Piperidinepropenoyl)-R-(-)nipecotyl-[(S)-2-benzyloxycarbonylamino-3- aminojpropionic add 2-(Piperidino)-2-oxoethyl ester • HCI. 14. The compound d daim 1 which is: N-3-(4-Piperidinepropionyl)-R-(-)-nipecotyl-{(S)-3-amino-3-(3-pyridyl)] propionic add 2-(Diethylamino)-2-oxoethyl ester. 15. A composition for treating platelet-mediated thrombic disorders comprising the compound d Claim 1 in an effective amount for treating such disorders in combination with a pharmaceutically acceptable carrier. 16. A method d making the composition d Claim 15 comprising mixing an effective amount d the compound with a pharmaceutically acceptable carrier. 17. A method of treating platelet-mediated thrombic disorders comprising administering to a patient afflided with such disorder an effective amount d the compound d Claim 1 to treat such disorder. 18. The method of Claim 17, wherein the amount is 0.1-300 mg/kg/day. 19. A method of treating platelet-mediated thrombic disorders comprising administering to a patient afflided with such disorder an effective amount d the composition of Claim 15 to treat such disorder. 20. A method of inhibiting platelet aggregation in a patient in need thered comprising administering to the patient an effective amount d the compound d Claim 1. 21. The method d Claim 20, wherein the amount is 0.1 -300 mg/kg/day.

Inventors: HOEKSTRA WILLIAM J, HOEKSTRA, WILLIAM, J.
Applicants: HOEKSTRA WILLIAM J, ORTHO MCNEIL PHARM INC, HOEKSTRA, WILLIAM, J., ORTHO-MCNEIL PHARMACEUTICAL, INC.
Application year: 1998
Main classification: C07D211
IPC codes: C07D211, C07D401